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EDUCATION
Elementary and Secondary Education:Amend Part3 ofArticle 16
of Chapter 2 of Title 20 of the Official Code of GeorgiaAnnotated,
Relating to Student Health in Elementary and Secondary
Education, so as to Require Immunization Against the Human
Papillomavirusfor Female Students Enteringthe Sixth Grade;
Providefor a BeginningDatefor Certain Requirements;Provide
for a Sunsetfor CertainRequirements;Providefor Related
Matters;Repeal Conflicting Law; andfor OtherPurposes

O.C.G.A. § 20-2-771(c) (amended)
SB 155
The bill would have required all female
students entering sixth grade to be
vaccinated
against
the
human
papillomavirus.
Exceptions
were
provided for children whose parents
objected on religious grounds. The bill
would have also suspended the
vaccination requirement in cases of
insufficient supplies of the human
papillomavirus vaccine. The bill would
have left unchanged requirements that
schools
keep
records
of the
immunizations and report to the
Department of Human Resources
annually.
N/A

CODE SECTION:
BILL NUMBER:
SUMMARY:

EFFECTIVE DATE:

History
Human Papillomavirus (HPV) currently infects a total of about 20
million people in the United States, and about 6.2 million Americans
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(men and women) get a new genital HPV infection each year.' The
Centers for Disease Control and Prevention (CDC) believes that 50%
or more of sexually active men and women are likely to acquire
genital HPV infections during their lifetimes. 2 Current statistics also
indicate that, by age fifty, "at least eighty percent of women will have
acquired a genital HPV infection." 3 Although most HPV-infected
individuals do not exhibit any symptoms associated with the
infection, in some individuals the infection may cause visible genital
warts, pre-cancerous changes in the genital or anal area, and, in some
cases, genital or anal cancer.4 Statistics show that of the total cases of
cervical cancer, 90% to 100% are associated with HPV.5 Moreover,
the rates of infection with HPV and mortality from associated
cervical cancer are highest in women of Hispanic descent and in
African American women. 6 However, the rates of new infections and
deaths from cervical cancer have decreased
steadily across all ethnic
7
and racial groups in the recent past.
In a recent report, the CDC explained that, "[a]pproximately 10 of
the 30 identified genital HPV types can lead, in rare cases, to
development of cervical cancer" and that "persistent infection [longer
than 2 years] with 'high-risk' types of HPV is the main risk factor for
cervical cancer." 8 CDC data also shows that although regular Pap
Tests, followed by medical observation and treatment if necessary,
can help prevent the onset of life-threatening conditions such as
cervical cancer, some women do not receive regular Pap Tests. 9 The
American Cancer Society estimates that 11,070 women will be
diagnosed with cervical cancer in 2008.10
1. See Ctrs. for Disease Control & Prevention, STD Facts-Human Papillomavirus (HPV),
http://www.cdc.gov/std/HPV/STDFact-HPV.htm (last visited Mar. 26, 2008) (hereinafter STD Facts].
2. Id.
3. See id.; see also Cal. Med. Assoc. (CMA) Found., Facts and Statistics,
http://www.calmedfoundation.org/projects/HPV/FactsStats.aspx (last visited Mar. 26, 2008) [hereinafter
CMA Foundation].
4. STD Facts, supranote 1.
5. CMA Foundation, supranote 3.
6. See id.
7. See Ctrs. for Disease
Control & Prevention,
Cervical
Cancer Statistics,
http://www.cdc.gov/cancer/cervical/statistics (last visited Mar. 26, 2008) [hereinafter Cervical Cancer
Statistics].
8. STD Facts, supra note 1.
9. See id.
10. Id
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On June 8, 2006, the Food and Drug Administration (FDA)
approved Gardasil, a recombinant DNA vaccine which is "the first
vaccine developed to prevent cervical cancer, precancerous genital
lesions and genital warts due to human papillomavirus (HPV) Types
6, 11, 16 and 18" for use in females ages nine to twenty-six." The
vaccine is manufactured by Merck & Co., Inc.12 GlaxoSmithKline is
currently expecting its own vaccine, Cervarix, intended to target HPV
strains 16 and 18, to receive FDA approval. 13 Merck's vaccine,
Gardasil, can be administered as three injections during a six month
period.14 Vaccination with Gardasil may "prevent most cases of
cervical cancer due to the HPV types 6, 11, 16 and 18."'15 However,
as the FDA has explained, because "Gardasil does not protect against
less common HPV types not included in the vaccine,. . . routine and
regular pap screening remain critically important to detect
precancerous changes in the cervix to allow treatment before cervical
cancer develops."' 16 Ideally, these screenings should begin no later
than at age twenty-one and should initially be performed every year
or every two years, depending on the type of test used. 7 Moreover,
women already infected with HPV before immunization would not
receive any protective health benefits from post-infection
vaccination, a fact which highlights the importance of vaccination
before any potential exposure to the HPV virus.18
To determine the efficacy of the vaccine, three multinational and
one U.S.-based study were performed on 21,000 female subjects
between the ages sixteen and twenty-six. 19 The international clinical
11. Press Release, U. S. Food and Drug Admin. FDA Licenses New Vaccine for Prevention of
Cervical Cancer and Other Diseases in Females Caused by Human Papillomavirus (June 8, 2006),
available at http://www.fda.gov/bbs/topics/NEWS/2006/NEW01385.html [hereinafter FDA Press
Release].
12. Id.
13. See
Nat'l
Conference
of
State
Legislatures,
HPV
Vaccine,
https://www.ncsl.org/programs/health/HPVvaccine.htm (last visited Mar. 26, 2008) [hereinafter State
Legislatures].
14. See FDA Press Release, supra note 11.
15. Id.
16. Id.
17. See Am. Cancer Soc'y, Guidelines for the Early Detection of Cancer,
http://www.cancer.org/docroot/PED/content/PED_2_3XACSCancerDetectionGuidelines_36.asp
(last visited Mar. 26, 2008).
18. FDA Press Release, supra note 11.
19. Id.
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studies indicated that in previously uninfected women, the vaccine
was almost 100% effective in the prevention of cervical, vaginal, and
vulvar precancerous lesions, as well as genital warts, for a period of
up to four years.20 Three additional studies were performed, one on
younger females, ages sixteen to twenty-six, in order to determine the
efficacy of the vaccine in this age group, and two which tested the
immune response of girls age nine to fifteen. 2 1 The studies showed a
stronger response in the nine- to fifteen-year-old age group than in
the sixteen- to twenty-six-year-old group; the FDA found this result
sufficiently significant to extend the results of the efficacy study on
22
the sixteen-twenty six year-old group to the younger group.
However, ethical and logistical considerations prevented a complete
23
effectiveness study on the nine- to fifteen-year-old group.
Furthermore, safety studies were conducted on a group of
approximately 11,000 individuals. 24 The worst side effects to the
vaccine in this study were "mild or moderate local reactions, such as
pain or tenderness at the site of injection.' 25 The drug producer
Merck further agreed that, after the licensing of the vaccine, it would
perform several additional tests, "to better understand [the vaccine's]
general safety and long-term effectiveness. 26 Later, in June 2006, the
CDC Advisory Committee on Immunization Practices unanimously
recommended
that girls aged eleven and twelve should receive the
27
vaccine.
In the wake of these events, at least thirty-nine states and the
District of Columbia moved to introduce legislation mandating,
20. See id; see also FDA Update: FDA Approves HPV Vaccine, NCI CANCER BULL. (Nat. Cancer
Inst., Rockville, Md.), June 13, 2006, at 5,
http://www.cancer.gov/NCICancerBulletin/NCICancerBulletin_061306.pdf [hereinafter NCI CANCER
BULLETIN].

21. FDA Press Release, supranote 11; see also NCI CANCER BULLETIN, supra note 20.
22. FDA Press Release, supranote 11; see also NCI CANCER BULLETIN, supra note 20.
23. NCI CANCER BULLETIN, supra note 20.
24. FDA Press Release, supranote 11.
25. Id.
26. Id.
27. See HPV Vaccine Legislation Introduced in Colorado, Connecticut, Kansas, Michigan,
Wisconsin; Maryland Bill to be Withdrawn, MED. NEWS TODAY, Feb. 5, 2007,
http'//www.medicalnewstoday.com/medicalnews.php?newsid=62117; State Legislatures, supra note 13;
see also CTRS. FOR DISEASE CONTROL & PREVENTION, HPV VACCINE QUESTIONS AND ANSWERS

(2006), http://www.cdc.gov/std/HPV/STDFact-HPV-vaccine.htm

[hereinafter HPV QUESTIONS AND

ANSWERS].
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funding, or educating the public about the HPV vaccine." In New
Hampshire, the State Health Department announced that it would
make the vaccine available free of cost to girls eighteen years or
younger. 29 In January 2007, South Dakota's Governor proposed a
like plan which would have been funded by $7.5 million from federal
vaccine funds and $1.7 million from general state funds.3 ° By mid2007, at least twenty-one states had considered introducing
legislation specifically mandating the HPV vaccination of middle
school age girls. 3 1 In March of 2007, the Virginia Legislature passed
32
such a bill, later incorporating additional parental exemption rights.
In Texas, a similar bill met with opposition from parental rights
advocates and those who felt that the requirement was "simply a
money-making venture for Merck," who presently manufactures the
only FDA-approved vaccine against HPV.3 3 To overcome this
opposition, on February 2, 2007, Texas Governor Rick Perry signed
an executive order mandating the HPV vaccination of girls eighteen
years-old or younger, while at the same time permitting parents to opt
out of the program and to benefit from privacy safeguards.3 4 The
Texas Legislature responded by rejecting the Governor's executive
order and instead sent him a bill that would prevent mandatory HPV
vaccinations for at least four years. 35 The Governor then retreated
from his mandatory vaccination plan and allowed the bill blocking
officials from requiring the shots to become law in the absence of his
36
signature.
Opposition to a mandatory HPV vaccination program has focused
on concerns about the vaccine's cost, financing, safety, and parental

28. State Legislatures, supra note 13.
29. Id.
30. Id.
31. See ELENA CONIS & CAROL MEDLIN, HEALTH POLICY MONITOR, HPV VACCINATIONS IN
CALIFORNIA (2007), available at http://www.hpm.org/survey/us/c9/1.

32. State Legislatures, supra note 13.
33. Women's Health News, http://womenshealthnews.blogspot.com (Feb. 4, 2007, On the Texas
HPV Vaccine Law).
34. Exec. Order No. RP65 (Feb. 2, 2007), available at
http://www.governor.state.tx.us/divisions/press/exorders/rp65/view.
35. Liz Austin Peterson, Texas Showdown on HPV Vaccine Order, ASSOCIATED PRESS, Apr. 25,
2007.
36. Texas Governor Backs Down on HPV Vaccine Bill, ASSOCIATED PRESS, May 9, 2007, available
at http://www.msnbc.msn.com/id/! 8575675.
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right to refuse.3 7 Some have also expressed "moral objections"
related to mandating a vaccine for a disease that is sexually
transmitted.38 This has created a heated debate on the advantages and
disadvantages of requiring middle school girls to receive vaccination
against HPV.39
Bill Tracking
Considerationby the Senate
On February 14, 2007, SB 155, sponsored by Senator Don Balfour
(R-9th), was read for the first time in the Senate and was referred to
the Health and Human Services Committee.4 °
SB 155 was heavily debated in committee. 4 1 Supporters of the bill,
including the bill's sponsor, Senator Balfour, emphasized the fact that
the bill can save lives. 42 In addition, supporters pointed out that the
bill can also save money: Senator Balfour explained later that he
believes it makes sense to push SB 155 because "the cost of giving
the shot is substantially less than the cost of paying for cervical
cancer down the road.' 4
Senator Balfour moved to amend his bill in three ways: to make it
effective beginning with the 2008 school year; to include a sunset
clause that would rescind the legislation in 2011; and to rescind the
mandatory vaccination provision in case of a federal recall by the
FDA. 44 These changes were made to address the concerns of those
who had earlier expressed opposition to the bill.45 Regarding what
prompted the changes to his earlier bill, Senator Balfour stated, "I
was trying to do some kind of compromising in the bill to get a bill
37. State Legislatures, supranote 13.
38. Id
39. Id
40. State of Georgia Final Composite Status Sheet, SB 155, June 5, 2007.
41. See Interview with Sen. Don Balfour (R-9th) (Apr. 17, 2007) [hereinafter Balfour Interview].
42. Id.
43. Id.
44. See Email from Laurie Sparks, Legislative Assistant to Senators Don Thomas (R-54th) and
William Hamrick (R-30th), to author (May 7, 2007, 11:59 EST) (on file with the Georgia State
University Law Review) [hereinafter Sparks Email] (containing minutes from Senate Committee
meeting on SB 155); see also SB 155 (SCA), 2007 Ga. Gen. Assem.
45. See Balfour Interview, supranote 41.
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that we could pass. At the end I was willing to say that 'any parent
who wanted to opt out, could.' Still mandated, but any parent that
wants to opt out could. 'A6
Testimony from those opposed to the bill was then heard.47 Tanya
Ditty, representing Concerned Women for America, voiced her
organization's concerns at the committee meeting.48 In a separate
interview, while first establishing that her organization was "not
opposed to the HPV vaccine, or to a cure against cervical cancer" and
that her organization "fully [supports] advances in science," she
stated that her organization was opposed to a mandatory vaccination
program and enumerated several reasons underlying her
organization's opposition to the bill. 49 First, she stated that because
HPV is a sexually transmitted disease, requiring vaccination of girls
eleven- to twelve-years-old "would send a message" that girls at
those ages are expected to be sexually active. Moreover, she stated
that "because there are other sexually transmitted diseases out there,"
vaccinating only against HPV could lead to "a false sense of
security., 51 Another reason for the opposition to the bill was based on
parental rights concerns. 52 She stated that her organization thought
that a bill such as this was the "long arm of the government reaching
into the homes of America," interfering with the rights of parents to
decide what is best for their children. 53 Her organization thought that
"doctors and parents, who know [a young girl's] body best, should be
the ones to make the choice" whether to give that young girl the HPV
vaccine.54 In addition, she noted that Merck, the vaccine's
manufacturer, usually takes the initiative to educate the public and to
promote its own products, but that in this case, Merck has "taken a
back seat," expecting the state taxpayers to fund the campaign to
promote Gardasil and educate the public about HPV. 55 She also
46. Id.
47. Id.
48. See Balfour Interview, supra note 41; see also Telephone Interview with Tanya Ditty, State
Director, Concerned Women of America (May 9, 2007) [hereinafter Ditty Interview].
49. See Ditty Interview, supra note 48.
50. Id.
51. Id
52. Id.
53. Id.
54. Id.
55. Ditty Interview, supra note 48.
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stated that because Peach Care, the state's health insurance plan for
children of lower-income families, already has funding problems, a
program such as this one could not be easily supported with public
funds.56
Others, including Dr. Carolyn Garcia, representing United for Life,
Sadie Fields, representing the Georgia Christian Alliance, and Pat
Chivers, from the Archdiocese of Atlanta also spoke in opposition to
the bill.57 Diane Hutchins, representing the Peach State Health Plan,
and Helen Sloat, from the law firm of Nelson Mullins Riley &
Scarborough, LLP, voiced their support for the bill.58
Senator Johnny Grant (R-25th) then made a motion to table the bill
to allow the committee to change the language of the bill to satisfy
the concerns of those present.59 The motion failed.6 ° Senator Steve
Henson (D-41st) then moved to pass Senator Balfour's bill by
substitute, which Senator Nan Orrock (D-36th) seconded. 6 1 The
committee voted 8 to 3 to approve the bill and on February 28, 2007,
the Senate Committee favorably reported the bill.62
On March 1, 2007, the bill was read a second time.63 However, on
March 15, 2007, because of earlier opposition to the bill, Senator
Balfour decided that the bill should not be placed on the legislative
calendar for a full Senate debate during the 2007 session. 64 Senator
Balfour indicated that there was "just too much sentiment against the
bill., 65 However, Senator Balfour noted that the bill might be
considered again in 2008.66

56. Id.
57. See Sparks Email, supra note 44.
58. Id.
59. See id.
60. Id.
61. Id.
62. See id; State of Georgia Final Composite Status Sheet, SB 155, June 5, 2007.
63. State of Georgia Final Composite Status Sheet, SB 155, June 5, 2007.
64. Daily Women's Health Policy Report: Actions Taken on HPV Vaccine Proposals in Florida,
Georgia, North Carolina,
South
Dakota,
KAISERNETWORK.ORG,
Mar.
22,
2007,
http://www.kaisemetwork.org/Dailyreports/repreprorecent reports.cfin?drcat=2&show=yes&drD
ateTime=03-22-07#43759.
65. See Travis Fain, HPV Bill Deadfor This Session, Sponsor Says, MACON TELEGRAPH, Mar. 15,
2007.
66. Id.;
see also Balfour Interview, supra note 41.
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The Bill
SB 155 would have amended section (c) of Code section 20-2-771,
relating to immunization of students, to require that, "prior to
admission into the sixth grade at any school in the State of Georgia,
all female students must be vaccinated against human papillomavirus,
unless the parent or guardian of a student certifies in writing that he
or she cannot afford, with or without health care coverage, the costs
associated with the vaccination." 67 The bill allowed an exemption as
provided in O.C.G.A. § 20-2-771(e), which allows exemptions from
vaccination requirements for children whose parents object on the
basis of religious beliefs.68 The bill would have left unchanged the
portions of Code section 20-2-771, which require schools and
facilities to "maintain on file certificates of immunization for all
children attending the school or facility"
and "to report annually to
6
Resources."
Human
of
the Department
Analysis
The bill would have mandated vaccination against HPV for all
girls entering the sixth grade in the State of Georgia. This would have
been the second government-mandated vaccination against a sexually
transmitted disease, the first one being vaccination against Hepatitis
B. 70 Critics of mandatory vaccination argue that mandatory
vaccinations are most justified in cases of highly contagious airborne
diseases, such as measles or pertussis. 7 1 Because HPV is not a highly
infectious disease and does not present a risk of rapid transmission to
third parties, they argue that the primary motivation for the
vaccination against HPV should be to shield girls from the long-term
risks associated with HPV infection. 72 Other critics of the mandatory
67. SB 155, as introduced, 2007 Ga. Gen. Assem.
68. See id.
69. Compare SB 155, as introduced, 2007 Ga. Gen. Assem., with O.C.G.A. § 20-2-771(c) (2000).
70. See Lawrence 0. Gostin & Catherine D. DeAngelis, Editorial, Mandatory HPV Vaccination:
Public Health vs. Private Wealth, 297 JAMA 1921 (2007), available at http://jama.amaassn.org/cgi/content/full/297/17/1921. The majority of the arguments in this section are based on Dr.
Gostin and Dr. DeAngelis's JAMA editorial.
71. Id.; see also James Colgrove, The Ethics and Politics of Compulsory Vaccination, 355 NEW ENG.
J. MED. 23,2389 (2006), available at http://content.nejm.org/cgi/content/fuIi/355/23/2389.
72. Gostin & DeAngelis, supranote 70; see also Colgrove, supranote 71.
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vaccination have observed that while the vaccine may have potential
benefits for girls and women who are at high risk of getting cervical
cancer, this fact alone does not justify "subjecting millions to yet
another vaccine. ' '73 Therefore, they suggest that mandatory
vaccination programs can and should be more carefully developed.74
Lack of Efficacy Datafor Middle School-Aged Girls
Preventing HPV infection and related diseases such as cervical
cancer is undoubtedly a laudable public health goal.75 But some
critics doubt the true effectiveness of a mandatory HPV vaccine.76
They point out that although statistics indicate an increasing
prevalence of infection each year for ages fourteen to twenty-four
(44.8% for ages twenty to twenty-four years) and then a gradual
decline in infection rates through age fifty-nine (19.6% for ages fifty
to fifty-nine years), infections with high risk types of HPV are
relatively rare and not all of those infected with high-risk HPV strains
will actually develop cervical cancer. 77 Furthermore, they note that
although studies indicate that the vaccine is almost completely
effective in stopping infection with HPV types 6, 11, 16, and 18 and
related diseases and that the vaccine is safe for use in girls age nine to
fifteen years, 78 how effective the vaccine is among girls of this age
group has not yet been determined.79 It is true that inferences from
limited FDA studies suggest that the vaccine should be effective in
this age group; however, the lack of adequate effectiveness data in
the age group in which the vaccine would be mandated has been cited
as one of many concerns by those who oppose the mandatory

73. Posting of Christiane Northrup, M.D., to http://www.ghchealth.com/forum/vaccine-informationforum-13.php (Aug. 24, 2006, Does Your DaughterNeed the HPV Vaccine?) [hereinafter Northrup].
74. Gostin & DeAngelis, supranote 70.
75. See Northrup, supra note 73.
76. Gostin & DeAngelis, supra note 70.
77. Id.
78. Id.; see also supra text accompanying notes 19-20.
79. See Gostin & DeAngelis, supra note 70; see also Merck's GardasilNot Proven Safe for Little
Girls, PR NEWSWIRE, June 27, 2006,
http://www.redorbit.com/news/health/552025/mercks gardasil vaccine_notproven safe for littlegirl
s/index.html?source-rhealth [hereinafter GardasilNot Proven Safe].
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vaccination program.8s Moreover, critics point out that no long-term
safety studies exist, in part because the vaccine was "fast-tracked" by
the FDA and in part because there have been no opportunities for
long-term patient follow-ups.81 Other critics go further to suggest that
the vaccine is in fact dangerous, noting that when given in
combination with the meningitis vaccine, it has led to joint pain,
seizures, loss of consciousness,
and more than forty cases of
82
Guillain-Barre syndrome.
ParentalRights Concerns & Informed Consent Issues
Parental autonomy issues have been at the forefront of the debate
over compulsory HPV vaccination. 83 Medical and legal
commentators have expressed the view that, given the low overall
rates of infection of HPV types associated with cervical cancer
(3.4%) and that the long-term consequences of the vaccine are not yet
known, it may be "unwise" to require a young girl with a very low
lifetime risk of cervical cancer to be vaccinated perhaps against both
her and her parents' wishes. 84 Others have noted that making the
vaccine mandatory raises "unique ethical and policy issues,"
potentially protecting all members of the community, but also
infringing upon patient autonomy and violating informed consent
requirements. 85 Critics point out that mandating the HPV vaccine
may also increase parental anxiety about the safety of schoolmandated vaccinations. 86 Thus, critics note that an undesirable sideeffect of a compulsory vaccination program may be an increase in the
growing pattern of parental refusal of vaccinations and the
80. See supratext accompanying notes 20-22; Ditty Interview, supra note 48; see also GardasilNot
Proven Safe, supra note 79.
81. Bernadine Healy, Don't Rush to Judgment, U.S. NEWS & WORLD REP., Feb. 18, 2007, available
at http://health.usnews.con/usnews/health/articles/070218/26healy.htm; see also Gostin & DeAngelis,
supranote 70.
82. See Wendy Wright & Nancy Staible, HPV Mandates; Parents Trump Politics, 32 ETHICS &
MEDICS 1 (2007), availableat http://www.ncbcenter.org/en0707-1 .aspx.
83. See id; see also HPV Vaccination: Should States Make it Compulsory?, HEALTH & HEALTH
CARE IN SCH. (Ctr. for Health & Health Care in Sch., Washington, D.C.), Jan. 2007, at 2,
http://www.healthinschools.org/News-Room/EJoumals/Volume-7/Number-10/HPVVaccinationShould-States-Make-It-Compulsory.aspx [hereinafter Compulsory Vaccination].
84. See Gostin & DeAngelis, supra note 70.
85. Compulsory Vaccination,supranote 83.
86. Gostin & DeAngelis, supra note 70.
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heightening of parental and public fears regarding childhood
vaccinations.87 Senator Don Balfour (R-9th), the sponsor of the bill,
stated that he spoke with representatives of the U.S. Department of
Health and Human Services about the concern that there could be too
many "opt outs," which might affect parents' willingness to let their
children take other vaccines as well.8 Senator
Balfour felt that "this
89
[was] a valid concern, a very valid concern."
Economic & FinancingConcerns
A mandatory vaccination program also raises economic and
financing concerns. 90 States which make the vaccine mandatory must
address funding issues, such as Medicaid and State Children's Health
Insurance Program (SCHIP) 91 coverage for children who are
uninsured, and also whether to mandate coverage by private
insurance plans.92 Critics note that the predicted cost of the HPV
vaccine is $360 for a series of three vaccines, which places it among
the most costly immunizations. 93 States which have introduced HPV
legislation have provided different funding mechanisms for the
proposed vaccination programs. 94 Potential sources of funding are
private insurance companies, state or federally funded health
programs, or consumers themselves. 95 A bill introduced by the
Georgia House of Representatives in 2006 would have mandated

87. See R. Alta Charo, Politics, Parents, and Prophylaxis-MandatingHPV Vaccination in the
UnitedStates, 356NEw ENG. J. MED. 19, 1905-1908 (2007); Gostin & DeAngelis, supranote 70.
88. Balfour InterView, supra note 41.
89. Id.
90. See State Legislatures, supra note 13; see also Gostin & DeAngelis, supranote 70.
91. The State Children's Insurance Program (SCHIP) provides low-cost healthcare to needy families
and children. U.S. Dep't of Health & Human Servs., Low Cost Health Insurance for Families &
Children: Overview, http://www.cms.hhs.gov/LowCostHealthlnsFamChild (last visited Nov. 15, 2007).
It is a program jointly financed by the federal and state governments and administered by the states. Id.
92. See State Legislatures, supra note 13.
93. See Gostin & DeAngelis, supra note 70; see also RAPID PUB. HEALTH POLICY RESPONSE
PROJECT, GEORGE WASHINGTON UNIV. SCH. OF PUB.HEALTH & HEALTH SERVS., HPV VACCINATION:
IT
BE
RECOMMENDED
OR
REQUIRED?
(2007),
http://www.gwumc.edu/sphhs/about/rapidresponse/download/HPVVaccinePaper
SHOULD

available

at

(January_2007).pdf

[hereinafter GW PAPER].

94. See generally State Legislatures, supranote 13.
95. See generally id.; see also GW PAPER, supranote 93; Gostin & DeAngelis, supra note 70.
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96
private insurance coverage for the Georgia vaccination program.
Critics have pointed out that neither of these funding options is
problem-free. In particular, they note that health inequalities would
likely be amplified if consumers or insurers were required to pay,
because those in the lower economic brackets (who are most often
uninsured or underinsured) would likely find that they cannot meet
the expense of the vaccine. 98 Further, those who are insured would
likely find that the costs are passed to them through their insurance
premiums. 99 Although the current proposal in Georgia would not
have provided for state or federal funding of the vaccination program,
if the legislature were to provide for government funding, it would
most likely have to cut other public health programs to cover the cost
of this program.' 00 The fact that Peach Care, part of Georgia's SCHIP
program, temporarily ran out of money in March 2007 indicates that
the state would currently find 0 it difficult to fund an additional
mandatory vaccination program.' '

The "Government Contractor"Defense & Sovereign Immunity
Yet another issue raised by critics is the issue of compensation 10of2
individuals who may be injured as a result of taking the vaccine.
They note that those suffering from potential side effects of the
vaccine may find it difficult to recover for their injuries if courts were
to find that the manufacturer of the vaccine had decreased or perhaps
no civil tort liability because the program was governmentmandated. 0 3 Merck has raised this "government contractor defense"
in a Nevada case in a similar context, namely injuries caused to an
infant by the government-mandated measles, mumps and rubella
(MMR) vaccine. 10 4 Although the court in that case rejected this
96. HB 11, 2006 Ga. Gen. Assem., http://www.legis.state.ga.us/legis/2007_08/fulltext/hbl .htm; see
also State Legislatures, supranote 13.
97. See Gostin & DeAngelis, supranote 70.
98. Id.
99. Id.
100. Id.
101. Georgia's PeachCareProgramRunning Out of Funds, To Freeze Enrollment,AP/AUGUSTA
CHRON., Feb. 9,2007, available at http://www.medicalnewstoday.com/articles/62884.php.
102. See Gostin & DeAngelis, supranote 70.
103. Id.
104. See Allison v. Merck & Co., 878 P.2d 948 (Nev. 1994).
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defense as "ill-defined," especially because the vaccine was not
manufactured to government specifications, the dissenting opinion of
Justice Young thought the extension of "sovereign immunity" to
contractors who act "in the sovereign's stead" would have been
appropriate. 0 5 An additional issue and related question is whether the
government itself could face civil liability for injuries caused by the
vaccine. This is unlikely because the state's decision to mandate a
vaccination program is most likely to be deemed an exercise of a
political, discretionary governmental function and thus not subject to
civil liability. 10 6 As a solution, critics of mandatory HPV vaccination
programs have suggested that the state must also offer a state-funded
"compensation-system" such as the National Vaccine Injury
Compensation Program,
for individuals injured by a government107
vaccine.
mandated
ConstitutionalIssues
A mandatory vaccination program that is only applicable to girls
only may also raise equal protection issues. 108 By requiring only girls
to be vaccinated against HPV, the bill creates a facial, express
classification on the basis of gender. As a result the bill, if
challenged, would be subjected to intermediate scrutiny.'0 9 To
withstand scrutiny, the state would have to provide an "exceedingly
persuasive justification" by showing that the classification is
"substantially related" to an "important government interest."'1 10 The
state may point to the fact that only girls can get cervical cancer as an
"inherent difference" between the sexes that would justify the
classification. 11 This may be a sufficient justification, given that a
105. See id.at 959; see also id.at 970 (Young, J., dissenting) (citing Boruski v. United States, 803
F.2d 1421, 1430 (7th Cir. 1986)).
106. See O.C.G.A. § 50-21-24(2) (2006) ("The state shall have no liability for losses resulting from..
*[t]he exercise or performance of or the failure to exercise or perform a discretionary function or duty
on the part of a state officer or employee, whether or not the discretion involved is abused.").
107. Gostin & DeAngelis, supra note 70.
108. See id.; Women's Health News, http://womenshealthnews.blogspot.com (Feb. 6, 2007, Backlash
Against Texas HPV Vaccine Law Continues).
109. See United States v. Virginia, 518 U.S. 515, 533 (1996) (applying intermediate scrutiny to facial,
express gender-based classification).
I10. Id.
111. See Balfour Interview, supranote 41.
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gender classification which benefits rather than disadvantages women
because of biological differences between men and women may
satisfy equal protection requirements. 112 In addition, the state may
point to the fact that vaccinating only girls would reduce the cost of
administering the vaccine and thus alleviate some of the funding
concerns, in order to bolster its argument that it has an "important"
government goal. 113 However, this argument is unlikely to go very
far, because in Reed v. Reed 1 4 and Frontiero v. Richardson,115 the
Supreme Court has rejected administrative ease and convenience as
sufficiently important objectives to justify gender-based
discrimination.
Moreover, if boys also stand to benefit from the vaccine, the law
arguably is not justified by gender-based, "inherent" differences.
Arguably, in such a case, boys would be disadvantaged by this bill
because they could not benefit from the potential health benefits of
the state-funded vaccine, such as prevention of genital warts and rare
forms of cancers, like penile and anal cancer. 116 If studies that are
currently being done to determine the efficacy of the vaccine in
preventing HPV infection and disease demonstrate such an effect in
males, the vaccine is likely to be licensed and approved for use by
males as well.' 17 At such a time, it will be difficult to sustain a
classification on the basis of gender for receiving the vaccine.
Another argument against the bill would be that it cannot be
justified as a "benign," compensatory measure, because it burdens
rather than benefits women on account of a sex-based characteristic.
Requiring young girls and not boys to be subjected to a series of three
vaccinations and the additional health risks associated with the
vaccine is seen by some as a burden, not a benefit.1 18 As a result,
critics point out that questions of fairness and equality of treatment
may emerge, because young girls' publicly funded education would
112. See Virginia, 518 U.S. at 533-36 (1996) (noting that while "inherent" differences are no longer
accepted as a ground for race or national origin classifications, "physical differences" between men and
women are enduring and that classifications which are "benign" (benefiting women) may be
constitutional so long as they are not "mere rationalizations for actions in fact differently grounded.").
113. See Balfour Interview, supra note 41.
114. Reed v. Reed, 404 U.S. 71, 76 (1971).
115. Frontiero v. Richardson, 411 U.S. 677, 690-91 (1973).
116. See HPV QUESTIONS AND ANSWERS, supra note 27.
117. Id.
118. See, e.g., Ditty Interview, supra note 48
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be conditioned on submitting to a new vaccine, while boys would be
free to attend school without such compulsion.' 19 Again, the state
would have to offer an "exceedingly persuasive justification" for its
decision to vaccinate girls and not boys. 12 0 The government's interest
in preventing disease and promoting public health may be such an
important goal, sufficient to justify a mandatory vaccination program,
although the fact that the vaccine is not necessary to prevent
immediate
harm to others will weigh against the government
12 1
interest.

However, even if the government's interest in promoting public
health would be a sufficiently important government interest to
justify the mandatory vaccination program, the program may still fail
the second step of equal protection analysis. The "means" test of
intermediate scrutiny equal protection analysis requires that the
government achieve its important goal through means that are
"substantially related" to the advancement of that goal.122 To
establish this requirement, the state may be asked to show that it
could not accomplish its important goal by "gender neutral"
alternatives. 123 If HPV vaccination proves beneficial for both boys
and girls, the state could not justify its girls-only mandate on
traditional public health rationales-i.e. that it would promote the
public health and prevent disease-because requiring all children
(regardless of gender) to be vaccinated would 24be equally as effective,
if not more so, in achieving its intended goal. 1
Prognosis
Although bills mandating the HPV vaccine have been introduced
in at least thirty-seven states as of mid-2007, only the Virginia
Legislature passed a mandatory vaccination bill for girls entering

119. See Gostin & DeAngelis, supranote 70.
120. See United States v. Virginia, 518 U.S. 515, 533 (1996).
121. See Gostin & DeAngelis, supranote 70.
122. Id.
123. See Orr v. Orr, 440 U.S. 278, 282 (1979) (striking down a gender classification and noting that it
would "cost the State nothing more, if it were to treat men and women equally by making alimony
decisions independent of sex.").
124. See Gostin & DeAngelis, supranote 70.
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sixth grade. 125 In New Mexico, a similar bill was introduced and
passed out of both the House and the Senate, but Governor Bill
Richardson vetoed the legislation. 126 In Texas, after a "show-down"
between state lawmakers and the Governor, the legislature finally
defeated the Governor's efforts to mandate the vaccination
program. 127 Similar bills were introduced but later withdrawn in
California and Maryland. 128 However, programs to provide the
vaccine free of cost to girls eighteen years-old or younger have met
with success in New Hampshire and South Dakota. 129 Georgia's
experience could prove educational for the many other states that
have introduced similar legislation.'1 30 Although enthusiasm about the
development of a vaccine that could protect against cervical cancer
prompted legislation to be introduced in the vast majority of states, it
appears that there is currently not sufficient support for a mandatory
vaccination program, 13 1 especially for one that would be funded by
private insurance. 132 However, if children's health-care funding
concerns ease, perhaps a government-funded program, provided free
of cost to young girls, would meet with more success. In addition,
better addressing potential equal protection as well as remaining
scientific and medical questions may also increase support for a
vaccination program in Georgia as well as other states.
Adina S. Greiner

125.
126.
127.
128.
129.
130.
131.
132.

See State Legislatures, supranote 13; Gostin & DeAngelis, supranote 70.
See Balfour Interview, supra note 41.
See discussion supraHistory.
State Legislatures, supranote 13.
Id.
Id.
Id.
See id.
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